EGFR and non-small cell lung carcinoma: According to the 2023 Chinese Society of Clinical Oncology (CSCO) guideline for NSCLC, the preferred upfront treatment is the 3rd-generation EGFR-TKI, as it has demonstrated excellent efficacy compared with the other generations of EGFR-TKI (Chinese Association for Clinical Oncologists, 2023).